ANNX

ANNX

USD

Annexon Inc. Common Stock

$2.520-0.140 (-5.263%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$2.660

Haut

$2.670

Bas

$2.510

Volume

1.85M

Fondamentaux de l'Entreprise

Capitalisation Boursière

276.5M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

1.80M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $1.285Actuel $2.520Haut $7.85

Actualités Connexes

GlobeNewswire

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient

Voir plus
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical

Voir plus
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Annexon, Lowers Price Target to $14

HC Wainwright & Co. analyst Andrew Fein maintains Annexon with a Buy and lowers the price target from $20 to $14.

Voir plus
HC Wainwright & Co. Maintains Buy on Annexon, Lowers Price Target to $14

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.